Skip to main content

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Globe Newswire - Fri Apr 8, 2022

– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor –

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.